İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2020

Adverse Cardiac Events Related to Hydroxychloroquine Prophylaxis and Treatment of COVID-19

Dergi

Infectious Diseases and Clinical Microbiology
OpenAlex Açık erişim · hybrid SJR Q4 Atıf 10 Yüzdelik 82.0% FWCI 1.46
Yıl
2020
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS dergi adı Infectious Diseases and Clinical Microbiology
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

OpenAlex · İngilizce

Coronavirus disease 2019 (COVID-19) was recognized as pandemic by the World Health Organization (WHO) on March 11, 2020. The disease is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV). The measures to contain the spread of the disease such as, social-distancing, hand hygiene, contact thracing, and isolation of persons suspected or confirmed to have infection have been considered to be largely effective. Although no specific drugs for COVID-19 have been proven to be effective currently for either prophylaxis or treatment. However, hydroxychloroquine (HCQ) was suggested as one of the choices of drug, despite the lack of evindence based information. We present three case reports of cardiovascular adverse effects, with respect to its propensity to cause QT interval prolongation and potentially serious cardiac arrhythmias. Keywords: hydroxychloroquine , cardiac , adverse , prophylaxis , treatment , covid-19 .

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

10 atıf

OpenAlex cited_by_count (önbellek / veritabanı)

Yazarlar

  1. ÇAĞLAR ÇUHADAROĞLU ACIBADEM MEHMET ALİ AYDINLAR ÜNİVERSİTESİ
  2. ZEYNEP TUĞÇE SARIKAYA ACIBADEM MEHMET ALİ AYDINLAR ÜNİVERSİTESİ